ArticleMethods in molecular biology (Clifton, N.J.)2026
A Pichia pastoris Cell-Free Protein Synthesis Platform.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cell-free protein synthesis is an in vitro transcription and translation process that takes advantage of the fact that cell growth is dissociated from protein production. After cell cultures have grown to the optimal cell density, the cells are lysed while preserving the cellular machinery so that they can be used in an in vitro protein synthesis reaction. The system uses three main components: cell lysate, a reaction mix, and plasmid DNA. Protein production can be performed in hours on a lab bench, expanding the possibility to evaluate multiple plasmids at once without the need to transform and select positively expressing clones.The use of Komagataella phaffii to generate the lysate for cell-free protein synthesis has been shown with a number of different strains, including a ribosome-overexpressing strain, FHL1. The high cell densities result in a highly active lysate that has been shown to be capable of producing a variety of products, including human serum albumin and virus-like particles (VLPs). Furthermore, as a eukaryotic platform, the system is capable of performing post-transcriptional modifications such as creating disulfide bonds without the need for additional folding chaperones or supplements. Here, we describe the methods required for generating cell lysate, creating a reaction mix that has been optimized through design of experiments, optimizing the concentration of DNA template, and using a reporter protein to monitor expression yields. Harnessing the potential of CFPS using K. phaffii can lead to faster prototyping of vectors before strain construction, facilitating the rapid identification of optimal protein variants. It can also be used to produce proteins that are toxic to living cells, providing an alternative source of proteins for experimentation.
Indexed as
Identifiers
41028490What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.